On November 22, 2021, Kamada (NASDAQ: KMDA; TASE: KMDA.TA), a plasma-derived biopharmaceutical company, announced its (up to) $160 million acquisition of a portfolio of four U.S. Food and Drug Administration (FDA)-approved plasma-derived hyperimmune commercial products from Saol Therapeutics (“Saol”), a commercial specialty pharmaceutical company.
Naschitz Brandes Amir represented Kamada in the transaction. The team included senior partner Sharon Amir, partners Tuvia Geffen and Avishai Eliash, and associate Michal Gomel.
For more information, please see Kamada’s press release.